On June 28, 2024, Tongrentang Medical and Health, a Chinese medical group under Tongrentang, submitted its prospectus to the Hong Kong Stock Exchange and plans to list in Hong Kong. On July 26, the China Securities Regulatory Commission accepted its listing application, and the International Department of the China Securities Regulatory Commission issued supplementary materials requirements for Tongrentang Medical and Health (August 23, 2024 - August 29, 2024).

Tongrentang Medical and Health

Please provide a detailed explanation to the lawyer regarding the following matters for your company, and ask the lawyer to provide a clear legal opinion:

1. Has your company and its subsidiaries conducted the application of processing technologies such as steaming, frying, calcining, etc. for traditional Chinese medicine decoction pieces, and the production of confidential prescriptions of Chinese patent medicine? What is the situation of your company's subsidiary's broadcasting and TV program production and operation business? Does it comply with the relevant regulations for foreign investment access before and after this issuance and listing?

2. (1) What are the reasons for your company's implementation and planned implementation of business and asset restructuring before this listing? Do related transaction decisions, evaluations, pricing, and other procedures comply with relevant regulations for state-owned asset supervision and management? (2) Progress of procedures for identifying state-owned shareholders.

3. Does the relevant litigation cases of your company's subsidiary Beijing Tongrentang (Baoding) Directly Governed Chinese Medicine Hospital Co., Ltd. constitute a substantive legal impediment to this issuance and listing?

4. (1) What is the situation of your company and its subsidiaries in developing and operating apps, mini-programs, public accounts, etc.? Does it involve providing information content to third parties? If so, please explain the types of information content and the measures taken to ensure information content security. (2) The scale of collected and stored user information, the situation of data collection and use, and the arrangements or measures for personal information protection and data security before and after listing.

5. Are there any pledged, frozen, or other disputed situations for the shares held by shareholders participating in this "full circulation"?

Beijing Tongrentang Healthcare submitted an IPO prospectus and plans to list in Hong Kong with exclusive sponsorship from China International Capital Corporation.

Link to Beijing Tongrentang Healthcare IPO Prospectus:

https://www1.hkexnews.hk/app/sehk/2024/106578/documents/sehk24062800209_c.pdf